We have published our coverage of The Association for Research in Vision and Ophthalmology (ARVO) 2021 Meeting, which you can find on the ARVO 2021 meeting page. The meeting was very informative, and covered a range of topics relevant to both optometrists and ophthalmologists. The presenters provided insights on systemic conditions, dry eye disease, emerging technology, and new treatment techniques and approaches. To ensure that none of our readers miss the ARVO 2021 highlights, we pull together our key takeaways below, with links to the articles so you can stay updated:
Researchers compared the treatment effect of rAAV2/2-ND4 with a group of untreated patients after clinical trials showed an unexpected result. “This indirect comparison of 76 treated patients with an external control group of 208 untreated patients showed a clinically meaningful effect of gene therapy on visual outcomes in ND4-LHON patients,” the research shows.
Smartphone mobile apps are increasingly being designed to improve ophthalmic care. Investigators from the Bascom Palmer Eye Institute in Miami developed an app to support patients recovering from retinal detachment repair.
Patients with diabetic retinopathy (DR) face a higher risk of developing Alzheimer disease (AD) than those without DR, according to findings presented at the ARVO 2021 Annual Meeting. The study also shows having diabetes without DR reduces the risk of AD compared with patients who don’t have diabetes at all.
Researchers weighed the outcomes of patients who underwent 2 types of procedures used in the management of neovascular glaucoma. Both pars plana and anterior chamber Ahmed glaucoma valve implant placements were effective in lowering IOP and visual acuity.
Researchers evaluated systemic conditions’ associations with the severity of dry eye disease (DED) signs and symptoms via secondary analysis of the DREAM Study.
Investigators evaluate the potential for a procedure to effectively reopen an aggravated trabecular meshwork to improving control of IOP and reducing the number of drops required for treatment for patients with narrow angle glaucoma.
Keep checking back with Ophthalmology Advisor for more on ARVO 2021, and future ophthalmology meetings. Did we miss a particular presentation that you thought deserved a spotlight? Let us know, and we might feature a piece on it.